Sugi Predict

Sugi Predict / Compounds / SCHEMBL5425552

SCHEMBL5425552

SCHEMBL5425552

CCC(C)CNC(=O)c1ccc(C)nc1Cl

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 4/20 0.47
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ BRD4 O60885 2/20 0.40
▸ P2RX7 Q99572 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.38
▸ ADORA2A P29274 1/20 0.37
▸ PDCD1LG2 Q9BQ51 2/20 0.37
▸ CD274 Q9NZQ7 2/20 0.37
▸ NAMPT P43490 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2472437 0.86 EGFR (0.47) EGFRMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL2474259 0.86 EGFR (0.49) EGFRMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL30027960 0.82 EGFR (0.54) EGFRKMT2ASMN1; SMN2BRD4HSD17B10
SCHEMBL5438509 0.80 MEN1 (0.51) EGFRMEN1KMT2ASMN1; SMN2TSHR
SCHEMBL609574 0.77 EGFR (0.52) EGFRKMT2ASMN1; SMN2BRD4ADORA2A
SCHEMBL2473897 0.77 EGFR (0.51) EGFRKMT2ASMN1; SMN2BRD4RAB9A
SCHEMBL21676260 0.76 EGFR (0.54) EGFRTSHRADORA2A
SCHEMBL5433157 0.76 BRD4 (0.53) EGFRSMN1; SMN2BRD4TSHRHTT
SCHEMBL5430952 0.75 EGFR (0.50) EGFRKMT2ASMN1; SMN2BRD4P2RX7
SCHEMBL5423538 0.74 HPGD (0.48) EGFRMEN1KMT2ASMN1; SMN2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 — — US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 — — WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 — — US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 — — US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 — — US disclosed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 — — EP disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 — — US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 — — WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 — — WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 EGFR 414/4885MEN1 3821/4885KMT2A 4419/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 EGFR 414/4885MEN1 3821/4885KMT2A 4419/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 EGFR 566/4885MEN1 3137/4885KMT2A 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.